February 3, 2026
- Co-funded by the EU’s Modern Well being Initiative (IHI), the Philips-coordinated analysis consortium will mix superior medical imaging, robotic steerage applied sciences, and AI to standardize and improve the precision of minimally invasive most cancers therapies
- 5-year analysis program with complete price range of EUR 23.9 million consists of 5 medical research to validate the technical options, with the purpose of setting a brand new benchmark for precision, security, and effectivity in minimally invasive most cancers care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a world chief in well being expertise, right this moment introduced that the PreciseOnco consortium, coordinated by Philips, has been awarded funding from the EU’s Modern Well being Initiative (IHI) to advance precision most cancers therapy by means of the combination of superior medical imaging, robotic help, and minimally invasive therapies. The EUR 14.9 million public funding can be complemented by EUR 9 million in in-kind contributions and extra sources from business companions, supporting a five-year analysis and innovation program that additionally consists of 5 medical research.
“Sensible imaging and robotic precision are opening new prospects for minimally invasive most cancers therapy,” mentioned Bert van Meurs, Chief Enterprise Chief for Picture Guided Remedy at Royal Philips. “By combining spectral imaging, AI-powered software program and robotic steerage, we’re growing new options to assist physicians deal with most cancers with higher precision, confidence and velocity. This results in higher outcomes for sufferers and a extra environment friendly use of hospital sources. The PreciseOnco partnership brings collectively expertise, medical experience and affected person views to assist enhance the best way most cancers care is delivered.”
Innovation by means of public-private partnership
The PreciseOnco public-private partnership unites consultants from business, analysis organizations, medical societies and main European hospitals:
- Business companions: Philips, Quantum Surgical, and IGEA
- Analysis group: European Institute for Biomedical Imaging Analysis (EIBIR)
- Medical society: Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
- Tutorial companions: College Hospital Cologne (Uniklinik Koeln) in Germany, College Medical Heart Utrecht (UMCU) and Leiden College Medical Heart (LUMC) within the Netherlands, and two main college hospital networks in France: Help Publique–Hôpitaux de Paris (APHP; Hôpital Henri-Mondor) and Hospices Civils de Lyon (HCL)
By uniting Europe’s main medical experience and business innovation, PreciseOnco goals to set a brand new benchmark for precision, security, and effectivity in minimally invasive most cancers care.
The rising most cancers burden and precision therapy wants
Most cancers stays a number one well being problem, with roughly 2.7 million new diagnoses in Europe annually [1] with projections suggesting over 35 million new most cancers instances globally by 2050, representing a 77% enhance from 2022 [2]. In response to this rising problem, interventional oncology has emerged as a quickly evolving self-discipline that integrates medical imaging, oncology, and minimally invasive therapy approaches [3]. Such therapies – together with focused ablation, radioembolization, and electrochemotherapy – provide benefits over conventional surgical procedure, comparable to shorter restoration instances and fewer unwanted side effects; nevertheless, their effectiveness strongly will depend on the efficiency of medical imaging and the precision with which physicians can information devices to tumors.
Bringing superior expertise into the interventional room
The PreciseOnco consortium goals to develop a set of built-in applied sciences designed to take the following leap in precision most cancers care. Central to the analysis and innovation program is spectral imaging, a sophisticated type of CT and cone-beam CT that captures considerably richer details about tissue composition than typical imaging, enabling extra assured differentiation between tumors, vasculature, and wholesome tissue. By analyzing X-rays at totally different vitality ranges, spectral imaging permits physicians with higher readability to see precisely what tissues they’re treating.
To enhance this superior imaging expertise, PreciseOnco will combine robotic steerage methods that use real-time imaging knowledge to information interventional devices (one or a number of needles) with sub-millimeter precision. The consortium may also look to advance electrochemotherapy, a minimally invasive approach that mixes regionally administered electrical pulses with chemotherapy to selectively deal with most cancers tissue, with the purpose of maximizing tumor management whereas preserving surrounding wholesome tissue.
Crucially, all these applied sciences can be powered by AI algorithms designed to reinforce picture high quality, cut back radiation dose, streamline superior visualization software program and supply real-time intra-procedural suggestions on therapy success. This may permit physicians to verify that tumors have been totally handled earlier than the affected person leaves the working room.
Scientific research
The challenge is structured into a number of work packages protecting spectral imaging expertise improvement, AI primarily based picture processing, robotic steerage integration, multi-center medical validation, and well being financial evaluation. PreciseOnco will conduct 5 medical research spanning a number of most cancers varieties and interventional workflows, guaranteeing strong validation in actual world medical settings:
- VISTA (Digital Spectral Imaging for Superior Thermal Ablation Steering): Evaluating spectral imaging to enhance liver, kidney ablation procedures and liver radioembolization.
- SPOT ON (Spectral angiography-computed tomography to Optimize percutaneous Tumor ablation): Assessing spectral CT for higher tumor focusing on and therapy planning.
- HORA EST HCC 2: Combining thermal ablation with transarterial chemoembolization (TACE) in a single session for improved hepatocellular carcinoma therapy.
- SPECTRA-L (Spectral Efficiency Analysis of a CT-Outfitted Therapeutic Radiology Angio Suite in Liver): Testing spectral imaging for transarterial chemoembolization (TACE) procedures.
- LASER (Locoregional therApies Spectral Analysis of Responses): Growing imaging biomarkers to foretell therapy success throughout a number of most cancers varieties and interventional methods.
Collectively, these research will generate proof to assist the adoption of spectral imaging and robotic steerage throughout European most cancers facilities, extending entry to superior minimally invasive therapies to a bigger affected person inhabitants.
Philips and innovation public-private partnerships
Public-private partnerships play a significant position in advancing healthcare innovation. With over 40 years of expertise in shaping and main such partnerships, Philips sees them as a robust complement to its world R&D packages, serving to construct sustainable ecosystems that foster innovation. Philips’ broad imaging, image-guided remedy, and healthcare informatics portfolio helps clinicians visualize, assess, information therapy, and make sure outcomes – supporting extra exact and customized care. With improvements like Verida detector-based spectral CT totally powered by AI and Azurion image-guided remedy system, Philips continues to push the boundaries of imaging expertise, superior visualization and minimally invasive remedy worldwide.
The PreciseOnco challenge web site can be obtainable quickly at www.preciseonco.eu.
The CORDIS challenge web page for PreciseOnco could be accessed right here. The IHI factsheet for PreciseOnco could be discovered right here.
References
[1] European Most cancers Data System (ECIS) – jrc_CancerEstimates2022_factsheet.pdf.
[2] World Well being Group (WHO) – International most cancers burden rising, amidst mounting want for companies.
[3] International Interventional Oncology Market report – Interventional Oncology Market Measurement and Progress Evaluation Report.
This challenge is supported by the Modern Well being Initiative Joint Enterprise (IHI JU) below grant settlement No. 101252582. The JU receives assist from the European Union’s Horizon Europe analysis and innovation program and life science industries represented by COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. PreciseOnco is funded by the European Union, non-public members, and people contributing companions of the IHI JU. Views and opinions expressed are, nevertheless, these of the writer(s) solely and don’t essentially replicate these of the aforementioned events. Neither of the aforementioned events could be held chargeable for them.
For additional info, please contact:
Joost Maltha
Philips International Exterior Relations
Tel.: +31 610 558 116
E-mail: joost.maltha@philips.com
Steve Klink
Philips Medical and Scientific Communications
Tel.: +31 610 888 824
E-mail: steve.klink@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a number one well being expertise firm centered on bettering folks’s well being and well-being by means of significant innovation. Philips’ patient- and people-centric innovation leverages superior expertise and deep medical and shopper insights to ship private well being options for shoppers {and professional} well being options for healthcare suppliers and their sufferers within the hospital and the house.
Headquartered within the Netherlands, the corporate is a pacesetter in diagnostic imaging, ultrasound, image-guided remedy, monitoring and enterprise informatics, in addition to in private well being. Philips generated 2024 gross sales of EUR 18 billion and employs roughly 67,800 staff with gross sales and companies in additional than 100 nations. Information about Philips could be discovered at www.philips.com/newscenter.
Source link
#PreciseOnco #analysis #consortium #awarded #EUR #million #IHI #grant #drive #breakthroughs #precision #most cancers #therapy
